Accessibility Menu
 

2 Dividend Kings on Sale That Are Yielding More Than 4%

Before you rush out to buy these stocks, you should consider the risks that come with them.

By David Jagielski, CPA May 25, 2023 at 9:37AM EST

Key Points

  • AbbVie's Humira now faces competition from biosimilars, but things look more promising in the long run.
  • 3M's margins have been shrinking, but its biggest risk is the plethora of lawsuits relating to its earplugs.
  • Both of these companies have been raising their dividend payments for 50-plus years.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.